Abstract:Background: YKL-40, which is also known as Chitiniase 3-like 1, has been found to be up-regulated in many autoimmune diseases including asthma, systemic sclerosis and systemic lupus, etc. However, the relationship between serum levels of YKL-40 and one another common autoinmmue thyroid disease - Graves' disease (GD) has not yet been investigated.Objective: The current study was performed to investigate the correlation of serum YKL-40 levels with disease severity of initially diagnosed GD.Methods: A total of 142 newly diagnosed active GD and 137 healthy individuals were enrolled in the study. Methimazole was given to 55 GD patients and then 2-month study of follow-up was performed. A commercial ELISA kit was applied for the detection of YKL-40 in serum. Degree of goiter was assessed according to Pérez's Grade. Receiver operating characteristic (ROC) curve analysis was carried out to detect the diagnostic value of serum YKL-40 with regard to goiter degree. The velocity of the peak systolic blood-flow and the thyroid tissue blood flow (TBF) were examined using Color Flow Doppler ultrasonography (CFDU).Results: The patients with GD exhibited dramatically higher YKL-40 in serum compared to those of healthy controls (606.1 ± 149.8 pg/mL vs. 397.4 ± 95.1 pg/mL, P < 0.001). Positive associations of YKL-40 with free T3 (FT3) and T4 (FT4), as well as the negative correlation of YKL-40 with TSH in serum, were observed. Additionally, the YKL-40 in serum was dramatically reduced after methimazole intervention, and the correlation of the decline with the reduced FT3 and FT4 was also found (all P < 0.001). Serum YKL-40 levels were positively correlated with goiter degree. ROC curve analysis demonstrated that serum YKL-40 concentration may act as a decent marker for goiter degree. The positive correlations of YKL-40 in serum with the average superior thyroid artery velocity (STV) and thyroid tissue blood flow (TBF) were also observed.Conclusion: Our findings implicated that YKL-40 may be closely connected to the pathogenesis of GD. Increased YKL-40 levels are linked with disease severity of initially diagnosed GD.

The changes and significance of the renal function indicators in primary Graves disease patients before and after treatment

The Changes of the Shear Wave Velocities on Thyroid Tissues in Patients with Graves Disease and Its Correlation with Thyrotropin

Changes of serum FT3, FT4, sTSH, TRAb, TGA and TMA concentrations in Graves' patients treated with 131I and clinical significances

Predictive value of bone turnover markers and thyroid indicators for bone metabolism in GD patients after treatment

Study of renal damage associated with Graves disease

Increased YKL-40 Levels Are Linked with Disease Severity of Initially Diagnosed Graves’ Disease

Hepatic Dysfunction in Patients with Graves' Disease and Its Correlative Factors

Prediction of the Recurrence Risk of Graves' Disease after Antithyroid Drug Therapy

Analysis of iodine-131-induced early thyroid hormone variations in Graves' disease.

Changes of serum NT-proBNP concentration in patients with Graves' disease

Down-Regulated Resistin Level In Consequence Of Decreased Neutrophil Counts In Untreated Grave'S Disease

Analysis of the Three Series Cells of the Peripheral Blood of Graves's Disease Prevention

Changes of serum and urine β2-microglobulin of leukopenia in hyperthyroidism of Graves'disease before and after 131I therapy

Related factors in predicting relapse of Graves' disease after treatment with antithyroid drugs

Valuable Predictive Features of Relapse of Graves' Disease after Antithyroid Drug Treatment.

Study on the detection value of thyroid function and related antibody in Graves disease

The Effect of Radioiodine Treatment on the Characteristics of TRAb in Graves’ Disease

Absolute reduction in peripheral regulatory T cells in patients with Graves’ disease and post-treatment recovery

[Prognostic Factors in the Relapse of Graves Disease].

Effects of Thyrostatic Treatment on T,B Lymphocytes and Expression of Costimulatory Molecules on Pripheral Blood Lymphocytes of Patients with Graves' Disease

Changes of Thyroid Stimulating Antibody and Thyroid Stimulating Blocking Antibody in Treatment of Anti-Thyroid Drugs and Combining with Levothyrocine to Hyperthyroidism